Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Anaemia
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Anaemia
    TopAbstracts in Anaemia 09/03/2008 - (DGNews)
    TopAbstracts in Anaemia 08/20/2008 - (DGNews)
    New Test Measures Hepcidin, Can Help Diagnose Anaemias and Iron Disorders - (DGNews)
    TopAbstracts in Anaemia 08/07/2008 - (DGNews)
    Single Lot of Epoetin Alfa Recalled Due to Damaged Vials - (DGNews)

    News archive

     Recent webcasts/CME - Anaemia
    Bridging Interdisciplinary and Resource Gaps in CKD-Anemia Management

    Webcasts/CME archive

     Recent cases - Anaemia
      Severe Hemolytic Anemia as the First Manifestation of G6PD Deficiency in a Child with Acute Hepatitis A Infection
      Rare Ileal Localisation of Angiolipoma Presenting as Chronic Haemorrhage and Severe Anaemia: A Case Report
      Severe Thrombocytosis and Anemia Associated with Celiac Disease in a Young Female Patient: A Case Report
      Paroxysmal Cold Haemoglobinuria Leading to Acute Renal Failure: A Case Report
      Pancytopenia Due to Iron Deficiency Worsened by Iron Infusion: A Case Report

      Cases archive
        




      my personal edition > anaemia > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Case Report: Autoimmune Haemolytic Anaemia Responds to Treatment With Rituximab

      A DGReview of :"Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndrome"
      International Journal of Hematology

      01/08/2004
      By Emma Hitt, PhD


      A patient with relapsed autoimmune haemolytic anaemia (AIHA) and a history of Evans syndrome responded completely to treatment with rituximab, according to a new case report.

      Clinical manifestations of Evans syndrome include AIHA and immune thrombocytopaenia. Treatment options include steroids, splenectomy, and intravenous immunoglobulin but, often, the symptoms become refractory to treatment.

      According to the authors, corticosteroids are often effective as a first-line treatment for AIHA; however, there is no consensus regarding their use for second-line treatment. By comparison, immunosuppressive therapy has not consistently been shown to be effective in the treatment of refractory or relapsing AIHA.

      Rituximab is an antibody to the CD20 antigen found on the surface of B lymphocytes. Recent reports have suggested that rituximab has activity against cold agglutinin disease and AIHA in patients with lymphoma, as well as in systemic lupus erythematosus.

      In their case report, Anat Galor, MD, and Timothy O'Brien, MD, with the Case Western Reserve University School of Medicine, Cleveland, Ohio, United States, describe the case of a 43-year-old white male with a history of immune thrombocytopaenia, splenectomy, juvenile rheumatoid arthritis, and adult-onset Stills disease.

      The patient had previously been treated with steroids, splenectomy, intravenous immunoglobulin, plasmapheresis, staphylococcal Protein A immunoadsorption, and chemotherapy with cytoxan and vincristine.

      Rituximab was administered weekly at 375 mg/m2 for 4 doses. The drug was well tolerated, and the patient had only mild flu-like symptoms after the second dose. The patient's haematocrit increased and his lactate dehydrogenase (LDH) decreased. Platelets remained normal through the AIHA exacerbation, the authors note.

      Nine months after his initial treatment, the patient was still in remission.

      "Recent reports suggest that rituximab may be an effective treatment for chronic immune thrombocytopenia and steroid refractory AIHA associated with lymphoproliferative disorders," Drs. Galor and O'Brien note.

      "We report a complete response to this agent in a patient with AIHA but without such an underlying disorder. Larger studies will need to be conducted to confirm this finding," they suggest.

      Int J Hematol 2003;78:335-336. "Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndrome"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send